The NextGen S1-RBD Antibodies Test is a diagnostic tool designed to detect antibodies against the S1 receptor-binding domain (RBD) of the SARS-CoV-2 virus. Clinical application involves assessing an individual’s immune response post-COVID-19 vaccination or infection. Presence of antibodies suggests immunity, aiding in public health strategies. The test helps monitor vaccine efficacy and guide healthcare decisions. No specific symptoms are associated with the test itself; rather, it serves as a valuable indicator of immune status against COVID-19.